Richard Češka, Michal Vrablík, Klára Vrablíková
Therapy of hyperlipoproteinaemia (HLP) and dyslipoproteinaemia (DLP) has been generally accredited approach in primary and secondary prevention of cardiovascular diseases. Basic therapeutic procedure is non-pharmacological treatment, however, to gain target levels pharmacotherapy is an indisposable part of non-pharmacological precautions. The article deals with pharmacological possibility of decreasing of LDL-cholesterol levels, affecting HDL-cholesterol levels, and treatment of dyslipidaemia in metabolic syndrome. Treatment should be based on intervention studies evidence. New drugs that reduce levels of both the whole and LDL-cholesterols have been discovered. They are statins(rosuvastatin and pitavastatin) and inhibitors absorbant cholesterol (ezetimib) used mostly in combination. Affecting of HDL-level has been topical for several years. Not far is the time when first drugs from CETP inhibitors group which increase the HDL-cholesterol level more than 50 % will be available. Dyslipidaemia in metabolic syndrome is characterized by low HDL-cholesterol level, higher level of triglycerides and occurrence of atherogenous small dense LDL particles. Agonists of nucleic receptors PPAR, predominantly fibrates and litazones are used in treatment of dyslipidaemia of this type. Combination therapy is going to be used more frequently, reuse of niacin in combination with statin is also possible.